Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Plasmacytoma 1Pancreatic Neoplasms 1Neoplasms 1Homologous Recombination Deficient Solid Tumors 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Acrocephalosyndactylia 1

Interventions

Etoposide 78Carboplatin 67Cisplatin 46durvalumab 26Topotecan 26atezolizumab 20Radiotherapy 19Irinotecan 19Paclitaxel 17anlotinib 16apatinib 15Nivolumab 15Drug Therapy 12pembrolizumab 9Platinum 9toripalimab 8tislelizumab 8Gemcitabine 8Bevacizumab 8Temozolomide 7Radiosurgery 7PM 01183 7Ipilimumab 7Pemetrexed 6Docetaxel 6Albumin-Bound Paclitaxel 6olaparib 5amrubicin 5Sunitinib 5surufatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Small Cell Lung Carcinoma × Drug Combinations × Clear all
NCT04125693 2022-04-01

Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety

Bayer

Phase 2 Completed
1 enrolled
BreastGenitourinaryHead & NeckThoracic

Acrocephalosyndactylia, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡